Company Overview of Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc. engages in developing treatments for smoking cessation and other addictions. Its products include EMB-001, an addiction treatment that comprises benzodiazepine oxazepam and cortisol synthesis inhibitor metyrapone medications, which targets brain functions and acts by modulating various stress-related pathways to address the craving that drives addiction. The company was founded in 2005 and is based in Shreveport, Louisiana.
2031 Kings Highway
Shreveport, LA 71103
Founded in 2005
Key Executives for Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc. Key Developments
Similar Private Companies By Industry
|PolyMedica Pharmaceuticals (U.S.A.), Inc.||United States|
|Oncology Research Therapeutics||United States|
|Ortho Pharmaceutical Corporation||United States|
|Phoenix Laboratories Inc.||United States|
|Kremers Urban Pharmaceuticals Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Embera NeuroTherapeutics, Inc., please visit emberaneuro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.